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Corticotropin-releasing factor (CRF) is a hypothalamic neurohormone and an extrahypothalamic
neurotransmitter that regulates the hypothalamic-pituitary-adrenal (HPA) axis. The urocortins (UCN I,
UCN II and UCN III) are CRF-related peptides, which may also regulate the HPA axis directly or indirectly,
by modulation of extrahypothalamic neurotransmitters, such as amygdalar GABA and hippocampal
glutamate.
Our previous in vitro superfusion studies have already demonstrated that CRF and UCN I stimulate the
amygdalar GABA release in rats. The aim of the present study was to investigate the effects of CRF, UCN I,
UCN II and UCN III on the glutamate release elicited electrically from rat hippocampal slices in similar
in vitro conditions. In order to investigate the participation of CRF receptors (CRFR1 and CRFR2) in this
process, hippocampal slices were pretreated with antalarmin, a selective antagonist of CRFR1 or astressin
2B, a selective antagonist of CRFR2.
CRF and UCN I at 100 nM decreased significantly the hippocampal glutamate release evoked by
electrical stimulation. In contrast, 100 nM of UCN II and UCN III did not affect significantly the hippo-
campal glutamate release enhanced by electrical stimulation. The decreasing effects of CRF and UCN I
were reversed by antalarmin, but not by astressin 2B, both being administered in equimolar doses.
Our results demonstrate that CRF and UCN I inhibit the glutamate release in the hippocampus via
CRFR1 and that CRFR2 does not participate to this process. Based on the previous and the present results
we conclude that CRFR1 agonists can activate the HPA axis not only directly, but also indirectly by
increasing the amygdalar GABA release and decreasing the hippocampal glutamate release.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Corticotropin-releasing factor (CRF) is a hypothalamic neuro-
hormone and an extrahypothalamic neurotransmitter that medi-
ates the endocrine, autonomic and behavioral responses to stress
(Vale et al., 1981). As a hypothalamic neurohormone, CRF activates
the hypothalamic-pituitary-adrenal (HPA) axis (Carrasco and Van
de Kar, 2003). CRF is secreted from the paraventricular nucleus
(PVN) of the hypothalamus and released into circulation at the level
of median eminence; reaching the anterior pituitary it stimulates
the secretion of adrenocorticotrop hormone (ACTH), which on its
turn stimulates the production of glucocorticoids in the adrenaliology, University of Szeged,
Bagosi).cortex (Tsigos and Chrousos, 2002). The increase of plasma gluco-
corticoid concentration not only reflects the activation of the HPA
axis, but it exerts negative feedback effects on the hypothalamus,
the anterior pituitary and the hippocampus and positive feedback
effect on the amygdala (Herman and Cullinan, 1997).
As an extrahypothalamic neurotransmitter, CRF may also
modulate the HPA axis (Herman and Cullinan, 1997). CRF is also
synthesized in the central nucleus of the amygdala (CeA) found in
the vicinity of the medial nucleus of the amygdala (MeA) and the
ventral subiculum (vSub) region of the hippocampus (Reul and
Holsboer, 2002). Neurons from these regions (especially Mea and
vSub) send GABAergic or glutamatergic projections to the
GABAergic neurons of the bed nucleus of the stria terminalis (BNST)
and the peri-paraventricular nuclei (peri-PVN), which exert a tonic
GABAergic inhibition upon the paraventricular CRF synthesis/


































Fig. 1. The effects of CRF on the hippocampal glutamate release in rats. CRF (100 nM)
decreased significantly the fractional [3H]glutamate release from rat hippocampal
slices following electrical stimulation. Values are presented as fractional release
(%) ± SEM; the number of animals used was 2 for each experiment and the numbers of
slices is indicated in brackets. A probability level of 0.05 or less was accepted as a
statistically significant difference and indicated with * p < 0.05 for CRF vs. control.
Z. Bagosi et al. / Neurochemistry International 90 (2015) 67e7168amygdala through GABAergiceGABAergic disinhibition increases,
whereas the hippocampus through glutamatergic-GABAergic in-
hibition decreases the activity of the HPA axis, respectively
(Herman et al., 2003, 2004).
CRF acts through two distinct receptors, CRFR1 and CRFR2,
which seem to have antagonistic effects in the brain (Chang et al.,
1993; Van Pett et al., 2000). Activation of CRFR1 induces HPA axis
activation, anxiety and depression, while activation of CRFR2 pro-
duces anxiolytic and antidepressive effects (Bale and Vale, 2004;
Reul and Holsboer, 2002). However, our recent studies suggest
that the role of CRFR2 in the regulation of the HPA axis can be
inhibitory or stimulatory, depending on the actual concentration of
their agonists, the urocortins (Bagosi et al., 2013, 2014). The uro-
cortins (UCN I, UCN II and UCN III) are CRF-related peptides, with
similar chemical structure, but different pharmacological profile,
than that of CRF (Fekete and Zorrilla, 2007; Suda et al., 2004). In
contrast with CRF, which binds preferentially to CRFR1, UCN I has
equal affinity for both CRF receptors (Vaughan et al., 1995). UCN II
and UCN III bind selectively to CRFR2 (Lewis et al., 2001; Reyes
et al., 2001).
Our previous in vitro superfusion experiments have demon-
strated that CRF and UCN I stimulate the amygdalar GABA release in
rats and that this stimulatory effect is mediated via CRFR1, and not
CRFR2 (Bagosi et al., 2008). The aim of the present experiments was
to investigate the effects of CRF and urocortins on the hippocampal
glutamate release in rats in similar in vitro conditions.
2. Materials and methods
Male Wistar rats (Animal Husbandry Services, Domaszek,
Hungary) weighing 150e250 g were used. During the experiments
they were kept and handled in accordance with the instructions of
the University of Szeged Ethical Committee for the Protection of
Animals in Research which are concordant with the European
Communities Council Directive of 24 November 1986 (86/609/EEC).
The rats were decapitated and their brains were rapidly removed.
All efforts were made to minimize animal suffering and to reduce
the number of animals used (N ¼ 2 for each experiment). The
hippocampus was isolated and dissected in a Petri dish filled with
ice-cold Krebs solution (composition: 113 mM NaCl, 4.7 mM KCl,
1.2 mM MgSO4, 25 mM NaHCO3, 11.5 mM glucose, 1.2 mM KH2PO4,
2.5 mMCaCl2, pH 7.4; Reanal, Hungary) according to the Stereotaxic
Atlas Of The Rat Brain (Pellegrino et al., 1979). The extracted hip-
pocampus was cut with a McIlwain tissue chopper and slices of
300 mM were produced.
The hippocampal slices were investigated with in vitro super-
fusion method described originally by Gaddum (Gaddum, 1953).
The slices were incubated for 30 min in 8 ml of Krebs solution,
submerged in awater bath at 37 C and gassed through a single-use
needle with a mixture of 5% CO2 and 95% O2. During the incubation
[3H]glutamate (Biotrend Ltd., Germany) at 20 mM with a specific
activity of 40 Ci/mmol was injected into the incubation medium.
Two tritiated slices were transferred to each of the four cylindrical
perspex chambers of the superfusion system (Experimetria Ltd,
Hungary). A multichannel peristaltic pump (Gilson Minipuls 2,
USA) was used to maintain a constant superfusion rate of 200 ml/
min. The slices were superfused for 30 min to allow tissue equi-
librium. In order to determine the effects of different CRFR agonists
on the hippocampal glutamate release equimolar doses (100 nM) of
CRF, UCN I, UCN II or UCN III (Bachem Ltd., Germany) were added to
the perfusion medium, 20 min after the superfusion had started. In
order to determine the participation of CRF receptors in this process
100 nM of selective CRFR1 antagonist antalarmin or 100 nM of
selective CRFR2 antagonist astressin-2B (SigmaeAldrich Inc., USA)
were preadded to the perfusion medium, 10 min after thesuperfusion had started. The concentrations of the non-selective
agonists were selected based on preliminary experiments in
which 100 nM of CRF and 100 nM UCN I proved the most effective
in stimulating the hippocampal glutamate release. Using equimolar
concentrations of the selective agonists/antagonists was inspired
by our previous studies investigating the amygdalar and the hy-
pothalamic GABA release (Bagosi et al., 2008, 2012).
The superfusates were collected in Eppendorf tubes by a
multichannel fraction collector (Gilson FC 203B, UK) every 2 min.
After the first 2 min electrical stimulation consisting of square-
wave impulses (total duration: 2 min, voltage: 100 V, pulse
length: 5 ms, frequency: 10 Hz) was delivered to each of the four
chambers, as gold electrodes were previously attached to both
halves of the superfusion chambers and connected to an ST-02
electrical stimulator (Experimetria Ltd., Hungary). The fraction
collecting lasted 32 min, thus 16 fractions were obtained.
After the fraction collecting had finished, 3 ml of scintillation
fluid (Ultima Gold, PerkineElmer Inc., USA) were added to each
fraction and the remnants of the superfused brain slices, which
were previously solubilized in 200 ml of Krebs solution using an
ultrasonic homogenizer (Branson Sonifier 250, USA). The radioac-
tivity in the fractions and the homogenized tissue samples was
measured with a liquid scintillation spectrometer (Tri-carb 2100
TR, Packard Inc., USA). The fractional release was calculated as a
percentage of the radioactivity present in the collected sample
compared to the total radioactivity of the corresponding tissue.
The fractional release of glutamate was calculated by the area-
under-the-curve (AUC) method and statistical analysis of the re-
sults was performed by analysis of variance (SigmaPlot v11.0, Systat
Software Inc., USA). Differences between two areas were deter-
mined by Student's t test or two-way ANOVA followed by Tukey
post-hoc test and a probability level of 0.05 or less was accepted as
indicating a statistically significant difference.
3. Results
CRF and UCN I (both of 100 nM concentration) decreased
significantly the hippocampal [3H]glutamate release elicited by
electrical stimulation [t(6, 11) ¼ 2.816; p < 0.05 for CRF vs. the
control, and t(6, 11) ¼ 3.352; p < 0.05 or UCN I vs. the control]
(Figs. 1 and 2). In contrast, UCN II and UCN III (both of 100 nM


































Fig. 2. The effects of UCN I on the hippocampal glutamate release in rats. UCN I
(100 nM) decreased significantly the fractional [3H]glutamate release from rat hip-
pocampal slices following electrical stimulation. Values are presented as fractional
release (%) ± SEM; the number of animals used was 2 for each experiment and the
numbers of slices is indicated in brackets. A probability level of 0.05 or less was

































UCN III (6) 
Fig. 4. The effects of UCN III on the hippocampal glutamate release in rats. UCN III
(100 nM) did not influence significantly the fractional [3H]glutamate release from rat
hippocampal slices following electrical stimulation. Values are presented as fractional
release (%) ± SEM; the number of animals used was 2 for each experiment and the
numbers of slices is indicated in brackets. A probability level of 0.05 or less was
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Z. Bagosi et al. / Neurochemistry International 90 (2015) 67e71 69glutamate release enhanced by electrical stimulation (Figs. 3 and 4).
The effect of CRF [F(2, 31) ¼ 5.303; p < 0.05 for CRF vs. control] was
reversed remarkably by antalarmin [F(1, 31) ¼ 2.387; p < 0.05 for
CRF þ antalarmin vs. CRF alone], but not by astressin 2B, both being
administered in equimolar doses (100 nM). Also, the effect of UCN I
[F(2, 31) ¼ 15.712; p < 0.05 for UCN I þ antalarmin vs. UCN I alone]
was reversed completely by antalarmin [F(1, 31) ¼ 13.958; p < 0.05
for UCN I þ antalarmin vs. UCN I alone], but not by astressin 2B,
both being administered in equimolar doses (100 nM). CRF, UCN I,
UCN II or UCN III did not change the basal release of [3H]glutamate.
Nevertheless, antalarmin and astressin 2B alone, did not change the
stimulated release of [3H]glutamate (Figs. 5 and 6).Fig. 5. The effects of antalarmin (ANT) and astressin 2B (AST) on the hippocampal
glutamate release decreased by CRF in rats. Antalarmin (100 nM) increased remarkably
the fractional [3H]glutamate release decreased by CRF (100 nM) from rat hippocampal
slices following electrical stimulation, but astressin 2B (100 nM) did not change it
considerably. Antalarmin and astressin 2B alone were ineffective. Values are presented
as area-under-the-curve (AUC) ± SEM; the number of animals used was 2 for each
experiment and the numbers of slices is indicated on the columns. A probability level
of 0.05 or less was accepted as a statistically significant difference and indicated with *4. Discussion
Our results demonstrate that of CRF and UCN I inhibit the
glutamate release in the hippocampus via CRFR1, as the selective
































Fig. 3. The effects of UCN II on the hippocampal glutamate release in rats. UCN II
(100 nM) did not influence significantly the fractional [3H]glutamate release from rat
hippocampal slices following electrical stimulation. Values are presented as fractional
release (%) ± SEM; the number of animals used was 2 for each experiment and the
numbers of slices is indicated in brackets. A probability level of 0.05 or less was
accepted as a statistically significant difference.
p < 0.05 for treatment vs. control and **p < 0.05 for CRF þ treatment vs. CRF alone.release decreased previously by the non-selective CRFR1 agonists.
CRFR2 is not involved in this process, since the selective CRFR2
antagonist did not reverse the effects of CRF or UCN I and the se-
lective CRFR2 agonists UCN II and UCN III did not affect the hip-
pocampal glutamate release either.
Our previous in vitro superfusion study reported that CRF and
UCN I stimulate the amygdalar GABA release via CRFR1, but not
CRFR2 (Bagosi et al., 2008). We speculated that this amygdalar
GABA is released from both the MeA and the CeA, which respond to
distinct stressors and are thought to have divergent roles in HPA
regulation. Neurons from the MeA are activated following exposure
to emotional stressors including predator, social interaction, forced
swimming and restraint stress paradigms and send mainly
GABAergic projections to GABAergic neurons of BNST and the peri-
PVN which directly innervate the PVN leading to activation e
actually to disinhibitione of the HPA axis (Smith and Vale, 2006). In
contrast, the CeA is activated following exposure to homeostatic
stressors, including hemorrhage and immune challenge and exerts
its feed-forward effect on the HPA axis through interneurons
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Fig. 6. The effects of antalarmin (ANT) and astressin 2B (AST) on the hippocampal
glutamate release decreased by urocortin I (UCN I) in rats. Antalarmin (100 nM)
reversed completely the fractional [3H]glutamate release decreased by UCN I (100 nM)
from rat hippocampal slices following electrical stimulation, but astressin 2B (100 nM)
did not change it considerably. Antalarmin and astressin 2B alone were ineffective.
Values are presented as area-under-the-curve (AUC) ± SEM; the number of animals
used was 2 for each experiment and the numbers of slices is indicated on the columns.
A probability level of 0.05 or less was accepted as a statistically significant difference
and indicated with * p < 0.05 for treatment vs. control **p < 0.05 for UCN I þ treatment
vs. UCN I alone.
Z. Bagosi et al. / Neurochemistry International 90 (2015) 67e7170The present in vitro superfusion study completes our previous
report with the observation that CRF and UCN I inhibit the hippo-
campal glutamate release via CRFR1, and not CRFR2. We presume




























Fig. 7. The effects of CRF and urocortin I (UCN I) on the amygdalar GABA and the
hippocampal glutamate release and their putative impacts on the hypothalamic-
pituitary-adrenal (HPA) axis. CRF is secreted from the paraventricular nucleus (PVN)
of the hypothalamus and released into circulation at the level of median eminence;
reaching the anterior pituitary it stimulates the secretion of adrenocorticotrop hor-
mone (ACTH), which on its turn stimulates the production of glucocorticoids in the
adrenal cortex. The increase of plasma glucocorticoid concentration not only reflects
the activation of the HPA axis, but it exerts negative feedback effects on the hypo-
thalamus, the anterior pituitary and the hippocampus and positive feedback effect on
the amygdala. CRF is also synthesized in the central nucleus of the amygdala (CeA)
found in the vicinity of the medial nucleus of the amygdala (MeA) and the ventral
subiculum (vSub) region of the hippocampus. Neurons from these regions (especially
MeA and vSub) send GABAergic or glutamatergic projections to the GABAergic neurons
of the peri-paraventricular nuclei (peri-PVN), which exert a tonic inhibition upon the
paraventricular CRF synthesis/release. Thus, the amygdala through GABAer-
giceGABAergic disinhibition increases, whereas the hippocampus through
glutamatergic-GABAergic inhibition decreases the activity of the HPA axis, respectively.
Based on the previous and the present results we propose that CRFR1 agonists can
activate the HPA axis not only directly by stimulating the pituitary ACTH (via CRFR1)
and consequently the adrenal glucocorticoid secretion, but also indirectly by increasing
the amygdalar GABA release (via CRFR1) and decreasing the hippocampal glutamate
release (via CRFR1).vSub region of the hippocampus, which has been implicated in the
regulation of the HPA axis. Hippocampal lesions involving the vSub
were shown to produce exaggerated HPA responses to restraint and
open field exposure, but not to hypoxia or ether exposure, sug-
gesting that hippocampal neurons respond to distinct stress mo-
dalities (Smith and Vale, 2006). Neurons from this region send
mostly glutamatergic projections to GABAergic neurons of BNST
and the peri-PVN which directly innervate the PVN, resulting ul-
timately in inhibition of the HPA axis (Smith and Vale, 2006).
The interaction of CRF and urocortins with glutamate have been
investigated in other in vitro settings also. An earlier study indi-
cated that CRF and UCN I modulate differently the excitatory glu-
tamatergic synaptic transmission in the CeA and the lateral septum,
which are reciprocally innervated (Liu et al., 2004). Another study
concluded that UCN I, but not UCN II, protects cultured hippo-
campal neurons from oxidative stress and glutamatergic excito-
toxicity via CRFR1, even more potently than CRF does (Pedersen
et al., 2002). We suggest that besides having role in neurotrans-
mission and neuroprotection, CRF-glutamate and UCN I-glutamate
interactions may also take part in the regulation of the HPA axis.
Based on the previous and the present results, we propose that
CRFR1 agonists can activate the HPA axis not only directly by
stimulating the pituitary ACTH and consequently the adrenal
glucocorticoid secretion, but also indirectly by increasing the
amygdalar GABA release and decreasing the hippocampal gluta-
mate release (Fig. 7).
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